BND-35

BND-35

BND-35 is an innovative antibody targeting the Ig-like transcript 3 (ILT3) receptor, in development for the treatment of solid tumors known to have a suppressive tumor microenvironment (TME). BND-35 is planned to enter Phase 1 clinical development in Q1 2024.

ILT3 is a key protein expressed by suppressive myeloid cells, including tumor-associated macrophages, myeloid-derived suppressor cells and tolerogenic dendritic cells. ILT3 enhances the activity of suppressive myeloid cells and therefore suppresses T cell activity in the TME by suppressing different mechanisms simultaneously.

BND-35 has been shown in preclinical studies to enhance anti-tumor activity by different suppressive T-cell environments and to enhance anti-tumor activity in various models. The antibody is in advanced pre-clinical development stages.